NASDAQ:SLDB Solid Biosciences Q1 2026 Earnings Report $6.85 -0.13 (-1.86%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$6.86 +0.01 (+0.07%) As of 10/2/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Solid Biosciences EPS ResultsActual EPS-$0.52Consensus EPS -$0.40Beat/MissMissed by -$0.12One Year Ago EPSN/ASolid Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolid Biosciences Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsSolid Biosciences' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Solid Biosciences Earnings HeadlinesSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1 at 4:05 PM | globenewswire.comSolid Biosciences: A Funded Challenge To Duchenne Gene Therapy's LimitationsSeptember 25, 2026 | seekingalpha.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 3 at 1:00 AM | InvestorPlace (Ad)RBC Capital initiates coverage of Solid Biosciences at outperformSeptember 17, 2026 | msn.comSolid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC SaysSeptember 16, 2026 | finance.yahoo.comSolid Biosciences wins new Outperform at RBC on DMD opportunitySeptember 16, 2026 | seekingalpha.comSee More Solid Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email. Email Address About Solid BiosciencesSolid Biosciences (NASDAQ:SLDB) is a biotechnology company focused on developing genetic medicines for patients with rare diseases. The company’s research platform is centered on adeno-associated virus (AAV) gene therapy and other genetic medicine technologies intended to address the underlying causes of disease. Solid Biosciences’ lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a severe inherited neuromuscular disorder. The company is also developing additional programs for rare cardiac and neuromuscular conditions, including SGT-501 for BAG3-associated dilated cardiomyopathy. These candidates remain in clinical or preclinical development, and the company does not have an approved commercial product. Founded in 2013, Solid Biosciences is headquartered in the United States and conducts research and clinical development activities through U.S.-based operations and collaborations. The company is led by Chief Executive Officer Bo Cumbo. Its programs are designed for patients with serious rare diseases in the United States and potentially other markets, subject to clinical and regulatory outcomes.View Solid Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
